Published in Cancer Res on August 01, 2008
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A (2011) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res (2009) 1.76
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res (2012) 1.71
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res (2015) 1.70
Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene (2013) 1.67
Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res (2011) 1.58
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res (2014) 1.55
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res (2014) 1.51
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther (2010) 1.46
Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. PLoS One (2016) 1.40
Cabazitaxel. Nat Rev Drug Discov (2010) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A (2010) 1.32
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol (2015) 1.26
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med (2011) 1.24
Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol (2013) 1.23
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res (2008) 1.21
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
New frontiers in androgen biosynthesis and metabolism. Curr Opin Endocrinol Diabetes Obes (2010) 1.19
Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol (2010) 1.16
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16
5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate (2010) 1.15
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol (2011) 1.14
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res (2013) 1.13
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci (2011) 1.11
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol (2013) 1.11
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res (2012) 1.10
AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 1.09
Is statin use associated with prostate cancer aggressiveness? BJU Int (2009) 1.09
Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One (2012) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem (2012) 1.08
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist (2012) 1.04
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Lipids and prostate cancer. Prostaglandins Other Lipid Mediat (2012) 1.01
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis (2012) 1.00
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem (2013) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res (2014) 1.00
Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res (2009) 0.99
Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett (2008) 0.99
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res (2011) 0.97
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids (2013) 0.97
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett (2011) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer. Front Oncol (2014) 0.96
Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One (2009) 0.96
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol (2014) 0.95
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorg Med Chem Lett (2012) 0.95
Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol (2012) 0.95
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med (2013) 0.95
CYP17 polymorphisms and prostate cancer outcomes. Prostate (2010) 0.95
Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One (2013) 0.94
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene (2008) 0.94
Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol (2015) 0.94
Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol Cancer Ther (2010) 0.93
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
Fish and chips: various methodologies demonstrate utility of a 16,006-gene salmonid microarray. BMC Genomics (2005) 1.75
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst (2013) 1.70
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther (2004) 1.63
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (2010) 1.59
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem (2007) 1.55
Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs (2002) 1.54
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum (2003) 1.50
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res (2004) 1.44
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem (2002) 1.44
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Prostate specific antigen: an updated review. Can J Urol (2003) 1.39
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int (2007) 1.38
miRDeep*: an integrated application tool for miRNA identification from RNA sequencing data. Nucleic Acids Res (2012) 1.37
Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene (2003) 1.32
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 1.28
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res (2002) 1.20
Loss of PTEN is associated with progression to androgen independence. Prostate (2006) 1.20
Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol (2007) 1.19
RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. J Biol Chem (2002) 1.18
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res (2012) 1.17
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int (2008) 1.17
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res (2012) 1.16
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16
Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int (2011) 1.15
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2013) 1.12
Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. Cancer Nurs (2007) 1.12
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res (2010) 1.12
Molecular analysis of the multiple GroEL proteins of Chlamydiae. J Bacteriol (2003) 1.11
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Polychlorinated biphenyls interfere with androgen-induced transcriptional activation and hormone binding. Toxicol Appl Pharmacol (2002) 1.09
Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One (2012) 1.08
The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion. Oncogene (2003) 1.08
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol (2013) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem (2006) 1.06
Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol (2002) 1.05
Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer (2012) 1.05
Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res (2011) 1.05
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol (2005) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol (2014) 1.04
Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate (2004) 1.04
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci (2013) 1.04
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2013) 1.04
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res (2011) 1.02
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate (2004) 1.02
Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer (2009) 1.02
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int (2006) 1.02
The importance of integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer (2011) 1.02
Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer (2009) 1.01
Novel targets and approaches in advanced prostate cancer. Curr Opin Urol (2007) 1.01
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 1.01
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res (2005) 1.01
A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res (2011) 1.00
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology (2002) 1.00
Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int (2011) 0.99
Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2011) 0.99
Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. BJU Int (2012) 0.99